
Imeve
Health and biotechnology in animal nutrition.
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
$1.4m | Series A | ||
Total Funding | 000k |
Related Content
Established in January 1980, Imeve S.A. operates in the animal health and biotechnology sector, specializing in animal nutrition. The company was founded in Jaboticabal, São Paulo, by a group of professors from São Paulo State University (UNESP), including Fernando Ávila and Gustavo Nogueira da Costa. Their academic research background formed the foundation of the company, with an initial focus on bringing scientific discoveries directly to the agricultural field.
Imeve's business centers on the development, production, and commercialization of solutions for the veterinary market. Its client base includes producers in the cattle, poultry, swine, equine, goat, ovine, fish, and crustacean sectors, as well as the pet market. The company generates revenue through the sale of its extensive product portfolio, which is divided into four main lines: probiotic additives, supplements and premixes, animal health products, and pet products. Additionally, Imeve offers private label manufacturing services to other companies.
The company's core product offering revolves around its expertise in probiotics. Imeve is a pioneer in the technology of fermentation and lyophilization (freeze-drying) of ruminal and intestinal bacteria, holding exclusive strains registered with the Ministry of Agriculture, Livestock and Supply (MAPA). Its portfolio includes approximately 90 products designed to improve the microbiota and productivity of animals. A key milestone in the company's history was the investment received from the Criatec Fund in 2011, which facilitated the expansion of its manufacturing facilities, product portfolio, and commercial team. This partnership lasted a decade, after which the founders reacquired the fund's stake in 2021, regaining full control of the company. The company has reported significant revenue growth, an 880% increase over the decade of the fund's investment, and was valued at R$47 million in 2021. Imeve operates in a facility of over 6,000 square meters and exports its products to 13 countries, with plans to expand further into Asian and Latin American markets.
Keywords: animal nutrition, biotechnology, veterinary probiotics, animal health, feed additives, livestock supplements, poultry health, swine nutrition, aquaculture supplements, pet nutrition, bacterial fermentation, lyophilization, animal microbiota, private label veterinary products, agricultural biotechnology, Jaboticabal, UNESP, Fernando Ávila, Gustavo Nogueira da Costa, ruminal bacteria